Clinical trial NCT03687099: Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma
Official title: Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glioblastoma
Keywords: Glioblastoma
CD45
Lymphocytes
Microglia
Macrophage
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2018-09-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Histological samples of GBM

Brief summary: Despite advances in neurosurgery , radiotherapy and chemotherapy, the median survival in GBM patients is only 15 months from diagnosis. Immunotherapy by checkpoint inhibitors (PD1 /PDL-1) appears as a promising treatment for many cancers. However, first clinical results are disappointing for GBM. An hypothesis is the immunosuppressive activity from infiltrating non-tumor cells. Conversion of non-tumor cells from an immunosuppressive to an immuno-activating phenotype could be attempted in a therapeutic perspective.

Detailed description: An important and constant infiltration of cells marked with CD45 has been observed in 77 GBM studied for the prognostic value of PDL1 and IL17 infiltration (in association with Pr Ghiringhelli ; INSERM ; Dijon) . However, CD45 is present at the surface of all leucocytes. The purpose of this project is to better characterize the nature and functionality of the CD45+ cells that infiltrate GBM (lymphocytes and their sub-types, macrophages, microglial cells). Formalin-fixed paraffin-embedded GBM samples will be studied. A panel of immune cell antibody will be used for the immuno-histological (IH) study. Furthermore, the investigator will compare these data with those obtained by the nanoString technology, a multiplexed measurement of gene expression.

Eligibility criteria: Inclusion Criteria:

* Formalin-fixed paraffin-embedded GBM samples from tumor bank of the pathological laboratory of the University Hospital of Amiens-Picardie.
* Histologic diagnosis of a glioblastoma according to the WHO classification of central nervous system
* Radical surgical removal in order to have enough histological material and to homogenize the main prognostic factor that is the surgical removal.
* Patients with more than 18 years old.
* Patients informed who have signed a consent form for using the tumor for research purposes without personal benefit. If patients were died, absence of objection known for the anonymous use of the tumor for scientific purpose.
* Be insured under one social security system.
* Committee for the protection of persons approval.

Exclusion Criteria:

* Relapsed GBM
* Other brain tumors.
* Medical, psychological or social conditions not allowing the comprehension of the conduct of the study for patients able to give their opinion.
* Patient under curatorship.

Primary outcomes:
measure: number of cells which express CD45 in the immunological environment from GBM.
timeFrame: 1
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens-Picardie
Study officials:
References: